• Kexin Wang, Zhen Jiao, Hongxiang Chen, Xiaowan Liu, Jing Lu, Xuli Liu, Jinming Li, and Lin Wang.
• Gynecology Department, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China.
• Medicine (Baltimore). 2021 Jan 22; 100 (3): e23892e23892.

BackgroundIn recent years, several reports have tried to prove this connection between rs1800872 polymorphism in interleukin-10 and cervical cancer among different populations, but the results are debatable. Thus, we collected all the published literature and conducted an integrated meta-analysis, which provided better evidence-based medicine for the relationship between rs1800872 polymorphism in interleukin-10 and risk of cervical cancer.MethodsWe systematically performed our search on PubMed, EMBASE, Web of Science, WanFang database, and CNKI for all papers related to this research, published up to August 1, 2020. Summary odds ratios (OR) with 95% confidence interval (95% CI) were calculated in allelic, homozygous, heterozygous, dominant, and recessive model to appraise the association.ResultsThe meta-analysis included 8 studies containing 1393 cervical cancer cases and 1307 controls. The aggregate data under heterozygous model and dominant inheritance model (OR = 0.66, 95% CI: 0.55--0.80) indicated a significant association between rs1800872 and the low risk of cervical cancer in the entire population. And the aggregated data under the dominant inheritance model shows that rs1800872 is significantly associated with the reduction in the risk of cervical tumors in the entire population.ConclusionOur conclusion is that the AC/AA + AC variant of Rs1800872 indicates a protective effect in the development of cervical cancer.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…